Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Shares in Novavax almost doubled after Sanofi struck a licensing deal worth up to $1.2bn to commercialise ...
LONDON — Novavax, the beleaguered maker of a Covid-19 vaccine, just got a boost of its own. The French pharma company Sanofi on Friday said it had reached a licensing deal to sell Novavax’s ...
Sanofi will pay vaccine maker Novavax $500 million and take a small equity stake in the Maryland-based company as part of a broad COVID-19 shot alliance, the companies announced Friday. Through the ...
(Bloomberg) -- Novavax Inc. shares surged after the company signed a $1.2 billion licensing agreement with Sanofi that includes commercializing a combined Covid-19 and flu shot. Novavax will ...
Novavax Inc. shares surged after the company signed a $1.2 billion licensing agreement with Sanofi that includes commercializing a combined Covid-19 and flu shot. Novavax will receive $500 million in ...
Novavax Inc. NVAX-Q on Friday said it had struck a licensing deal worth at least US$1.2-billion with Sanofi SNY-Q for its COVID-19 vaccine in exchange for a stake that valued the U.S. biotech firm ...
Novavax shares (NVAX) surged after the vaccine maker said it had struck a licensing deal worth up to $1.4 billion with Sanofi (SNY, FR:SAN). Novavax shares were up 133% in recent trading at $10.11.
(Bloomberg) -- Novavax Inc. shares surged after the company signed a $1.2 billion licensing agreement with Sanofi that includes commercializing a combined Covid-19 and flu shot. Most Read from ...
LONDON — Novavax, the beleaguered maker of a Covid-19 vaccine, just got a boost of its own. The French pharma company Sanofi on Friday said it had reached a licensing deal to sell Novavax’s ...